Search
for
Sort by
Research 91–120 of 427
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
- Cutaneous drug reactions
- ASSOCIATION OF SYSTEMIC LUPUS ERYTHEMATOSUS AND CHRONIC GRANULOMATOUS DISEASE IN ADULTS: REPORT OF 2 CASES
- Resolution of Waldenström's macroglubulinemia related isolated neutropenia by immunochemotherapy
- Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
- Induction plus adjuvant chemotherapy, combined treatment with nimotuzumab, and intensity-modulated radiation therapy for N3 stage nasopharyngeal carcinoma
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- Chemotherapy-induced toxicity—a secondary effect caused by released DNA?
- Ayurveda-based Botanicals as Therapeutic Adjuvants in Paclitaxel-induced Myelosuppression
- Immune Cells in Cutaneous Wound Healing: A Review of Functional Data from Animal Models
- Safety assessment of cyclin-dependent kinase 4/6 inhibitors and comparison of time to adverse events
- Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
- Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics
- Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
- Animal models for the study of fetal tissue repair
- Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
- The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial
- Treatment of invasive aspergillosis with itraconazole
- Clinical Development of Topoisomerase-Interactive Drugs
- Innovative sequence of docetaxel–gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study
- Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
- Data from A Phase Ib Study of Chemoimmunotherapy with Pegylated Liposomal Doxorubicin and Pembrolizumab in Estrogen Receptor–Positive Metastatic Breast Cancer
- A phase 1b study of chemo-immunotherapy with pegylated liposomal doxorubicin and Pembrolizumab in estrogen receptor positive metastatic breast cancer
- Oral Signs of Hematologic Disease
- Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
- Managing the adverse effects of cytotoxic chemotherapy at the level of primary healthcare
- The JAK/STAT signaling pathway: from bench to clinic